Cardio Diagnostics Holdings Inc. (CDIO)
NASDAQ: CDIOHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CDIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.74M
- EPS (TTM)
- -$2.52
- Dividend yield
- None
- 52-week range
- 0.97 – 7.91
- Day range
- 1.53 – 1.68
- Volume / Avg
- 32.03K / 26.91K
- Beta
- —
- Shares outstanding
- 2.96M
52-week range
CDIO stock today
Cardio Diagnostics (CDIO) closed at $1.60 on Nov 20, down 3.03% (-$0.05), versus the S&P 500's 3.70% decline. Shares are 79.8% below their 52-week high of $7.91 and 64.9% above the 52-week low of $0.97, near the bottom of the past year's range. Cardio Diagnostics has posted a net loss over the last twelve months (EPS of -$2.52), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cardio Diagnostics
Company profileCardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Dr. Meeshanthini V. Dogan Ph.D.
- Headquarters
- Chicago, IL
- Employees
- 15
- IPO year
- 2022
- Website
- cdio.ai
Financial highlights
Full financialsIn fiscal 2025, Cardio Diagnostics generated $14,825 in revenue, down 57.5% from fiscal 2024, the first decline in the 5 years shown. Cardio Diagnostics reported a net loss of $6.5 million, compared with a loss of $8.4 million a year earlier. Operating margin was -43737.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $14.82K | $34.89K | $17.07K | $950 | $901 |
| Growth | -57.51% | +104.45% | +1696.32% | +5.44% | — |
| Net income | $-6.50M | $-8.38M | $-8.38M | $-4.66M | $-620.45K |
| EPS (diluted) | $-3.71 | $-9.35 | $-0.66 | $-1.51 | $-0.53 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 6, 2026
- EPS actual vs est.
- $-0.59 vs —
Cardio Diagnostics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BMRABiomerica Inc. | 1.08 | -0.92% | $4.97M | vs CDIO |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs CDIO |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs CDIO |
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs CDIO |
| VRAXVirax Biolabs Group Limited | 0.3319 | -12.89% | $446.40K | vs CDIO |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs CDIO |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs CDIO |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs CDIO |
Indexes, lists and sector
Cardio Diagnostics stock FAQ
What is Cardio Diagnostics's stock price today?
CDIO last traded at $1.60 as of Nov 20, 4:00 PM EST, down 3.03% on the day. Prices are delayed at least 15 minutes.
Who is Cardio Diagnostics's CEO?
Dr. Meeshanthini V. Dogan Ph.D. is the chief executive officer of Cardio Diagnostics Holdings Inc., which has about 15 employees.
What is the CDIO 52-week high?
The 52-week high for CDIO is $7.91 and the 52-week low is $0.97. The stock is currently 79.8% below its high.